-
admin
Posts
Global Biomaterials Market Size To Exceed USD 528.5 Billion By 2033 | CAGR of 13.77%
The Global Biomaterials Market Size was Valued at USD 145.5 Billion in 2023 and the Worldwide Biomaterials Market Size is Expected to Reach USD 528.5...
Global Quartz Market Size To Exceed USD 12.2 Billion By 2033 | CAGR Of 5.42%
The Global Quartz Market Size was Valued at USD 7.2 Billion in 2023 and the Worldwide Quartz Market Size is Expected to Reach USD 12.2...
The Marquie Group Issues Shareholder Update
ST. PETERSBURG, Fla., June 25, 2024 (GLOBE NEWSWIRE) — The Marquie Group, Inc. (OTCMKTS:TMGI) Dear Valued Shareholders – we are pleased to announce the successful...
EHang Delivers 27 Units of EH216-S to Wencheng County and Completes First Passenger-Carrying Flight in Wencheng
GUANGZHOU, China, June 25, 2024 (GLOBE NEWSWIRE) — EHang Holdings Limited (“EHang” or the “Company”) (Nasdaq: EH), the world’s leading urban air mobility (“UAM”) technology...
Arthritis Foundation Launches Carolina Hills Classic Bike Tour, Coming June 2025
Producers of the California Coast Classic will create an all-new “Experience of a Lifetime” cycling event nestled in the iconic Blue Ridge Mountain foothills ASHEVILLE,...
Zealand Pharma announces completion of an upsized equity offering of 8.35 million new ordinary shares raising gross proceeds of USD 1 billion / DKK 7 billion
Company announcement – No. 35 / 2024 Zealand Pharma announces completion of an upsized equity offering of 8.35 million new ordinary shares raising gross proceeds...
Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
DALLAS, June 25, 2024 (GLOBE NEWSWIRE) — Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies...
Appili Therapeutics Reports Fiscal Year 2024 Financial and Operational Results
LIKMEZ™ (ATI-1501) for Metronidazole Oral Suspension 500mg/5mL launched and commercial sales ongoing Funding commitments from U.S. Air Force Academy intended to advance ATI-1701 toward an IND...
Fennec Announces Results of Annual Meeting
RESEARCH TRIANGLE PARK, N.C., June 25, 2024 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the...
Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 PNS Annual Meeting
ANX005-Treated Patients Demonstrated Faster and More Complete Recovery from Week 1 through Week 26 on Primary and Multiple Pre-Specified Endpoints Two and a Half Times...
